secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0000950170-25-009474
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics reports positive Phase 1 topline results for T1D therapy SAB-142; plans Phase 2b in 2025
--------------------------------------------------------------------------------

- Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.
- SAB-142 showed sustained immunomodulation with MoA analogous to rabbit ATG, correlative to C-peptide preservation.
- Company plans to advance SAB-142 into Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.
- Results presented at R&D webinar on Jan 28, 2025; KOL Michael Haller, MD from Univ of Florida participated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/0000950170-25-009474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/sabs-20250128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-009474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer